2023年7月31日

MORRISVILLE, N.C. – 2023年7月31日 – Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced that it has signed an agreement with Optimal Clinical Trials Ltd. The agreement will expand the Company’s clinical trial capabilities across a broad range of therapeutic areas in New Zealand, including Oncology, CNS and Vaccines.

Optimal Clinical Trials Ltd now joins the Syneos Health Catalyst Site Program, introduced in 2016 to strengthen collaborations with clinical research sites worldwide. The Catalyst Site Program harnesses insights from sites across the globe to drive continuous improvement and develop best practices in clinical research delivery. Together, Syneos Health and Optimal Clinical Trials Ltd will enable sites, sponsors and patients to collaborate in multiple therapeutic areas, fueling engagement through transparent communication channels during the entire clinical trial process.

“Our agreement with Optimal Clinical Trials Ltd is part of Syneos Health’s global strategy to accelerate our clinical development impact in this rapidly growing and changing market,” said Dr. Ken J. Lee, General Manager and Regional Head, Clinical Development, APAC, Syneos Health. “This collaboration supports our strong focus on customers, achieving consistent delivery and quality for their programs, and executing customized solutions that address their unique and complex needs.”

Dr Liz Smaill, General Manager at Optimal Clinical Trials Ltd welcomed the signature of the agreement: “Thank you for having Optimal Clinical Trials as a Catalyst site. We are looking forward to collaborating with Syneos Health as part of this program.”

Syneos Health has relationships with more than 100 Catalyst sites worldwide and the Company has been acknowledged by the Society for Clinical Research Sites as a recipient of the Eagle Award for demonstrating dedication to establishing strong site partnerships.

About Syneos Health
サイネオス・ヘルス®（Nasdaq：SYNH）は、お客様の成功を後押しすることを目的として設立された完全統合された大手バイオ医薬品ソリューション組織です。臨床、メディカルアフェアーズ、およびコマーシャル事業に関する独自のインサイトを最新の市場の実態に対応できるように変換しています。 

弊社は一丸となって、洞察を共有し、最新技術を活用し、高度なビジネスプラクティスを応用して、お客様の重要な治療法を患者様にお届けする期間を短縮します。

サイネオス・ヘルスは、同僚、お客様、患者様、コミュニティ、環境に配慮する、多様で公平、かつ包括的な社風を支持しています。 

To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.

Syneos Investor Relations Contact:  Ronnie Speight Senior Vice President, Investor Relations +1 919 745 2745 [email protected]

Syneos Press/Media Contact: Gary Gatyas Executive Director, External Communications +1 908 763 3428  [email protected]